Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) reported Q1 EPS of ($0.12), $0.01 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $450 thousand versus the consensus estimate of $500 thousand.

For earnings history and earnings-related data on Acadia Pharmaceuticals, Inc. (ACAD) click here.

Earnings